A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy
- 3 May 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 61 (3), 508-514
- https://doi.org/10.1016/j.jhep.2014.04.037
Abstract
No abstract availableFunding Information
- UCSF Liver Center Biostatistics Core (P30 DK026743)
This publication has 26 references indexed in Scilit:
- Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipientsLiver Transplantation, 2013
- Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteersJournal of Hepatology, 2012
- Review and management of drug interactions with boceprevir and telaprevirJournal of Hepatology, 2012
- Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimusJournal of Hepatology, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2011
- Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantationJournal of Hepatology, 2009
- Pegylated‐interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta‐analysis of prospective controlled studiesJournal of Viral Hepatitis, 2008
- A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantationLiver Transplantation, 2007
- Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative AnalysisAmerican Journal of Transplantation, 2006
- Pure red cell aplasia associated with concomitant use of mycophenolate mofetil and ribavirin in post-transplant recurrent hepatitis CTransplant International, 2006